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Boeckh M, Nichols WG et al, BBMT 2003) have demonstrated
that at least some CMV seropositive transplant recipients appear to
have a persistent mortality disadvantage when compared to their
seronegative counterparts. The speciﬁc transplant characteristics
that underlie this relationship remain unclear, but most studies
have focused on the impact of serostatus on mortality after T-cell
depleted transplantation. We tested the hypothesis that CMV
serostatus inﬂuences mortality among recipients of T-cell-replete
transplants from mismatched or unrelated donors (MM/URD, n
1001) but not matched sibling donors (MSD, n  749) in the
preemptive era. Methods: The impact of CMV serostatus ( or
) of the donor (D) and recipient (R) on overall mortality was
assessed among 1750 consecutive allogeneic HSCT recipients at
our center by means of multivariable regression models. Support-
ive care for this cohort included preemptive ganciclovir, which was
applied for any level of pp65 antigenemia and continued until day
100 after transplant. Results: Among recipients of transplants
from matched sibling donors, overall mortality among R and
D/R-patients was comparable to that of D-/R-patients after
adjusting for patient/donor age, underlying disease and disease-
speciﬁc risk, conditioning regimen, cell source, GVHD prophy-
laxis, cell dose, and year of transplant (Table). Overall mortality
was signiﬁcantly higher, however, among both seropositive recip-
ients and D/R-patients when compared to D-/R-patients in the
setting of mismatched sibling or unrelated donor (MM/URD)
transplantation. Formal tests for interaction according to donor
type yielded suggestive trends for the D-/R and D/R-groups
(p  0.13 and 0.16, respectively). Conclusions: Preemptive strat-
egies appear to be effective for recipients of MSD HSCT, yet fail
to eliminate the mortality associated with CMV seropositivity
among recipients of mismatched or unrelated donor transplants.
New drugs and new approaches (including possible re-examination
of antiviral prophylaxis) are clearly needed for these high-risk
patients.
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SOURCE OF DONOR STEM CELLS IMPACTS INCIDENCE OF BLEEDING
AND PLATELET AND RBC TRANSFUSION REQUIREMENTS DURING
STEM CELL TRANSPLANTATION (SCT): RESULTS OF THE PHASE III
SPRINT TRIAL OF INTERCEPT PATHOGEN INACTIVATED PLATELETS
Vesole, D.1, Stadtmauer, E.2, Goodnough, L.T.3, Coutre, S.4, Howard,
F.5, Lin, J.-S.6, Conlan, M.G.6, for the SPRINT Study Group 1. Med
College WI, Milwaukee, WI; 2. Univ of PA Health System, Philadel-
phia, PA; 3. Washington Univ Sch Med., St. Louis, MO; 4. Stanford
Univ Sch Med, Stanford, CA; 5. Loma Linda Univ Cancer Inst., Loma
Linda, CA; 6. Cerus Corporation, Concord, CA
Background: INTERCEPT Platelets (IP) are prepared with
Helinx® technology (amotosalen HCl and UVA) to inactivate a
broad range of viruses, bacteria, and protozoa, as well as WBCs
which can cause transfusion reactions and TA-GVHD. Methods:
A double-blind, parallel group Phase III trial (SPRINT) random-
ized patients (pts) with malignancy undergoing chemotherapy only
(CTX) (19%) or SCT (78%) to treatment with IP or Reference
(RP) platelet (plt) transfusions (tx) for up to 28 days. The prophy-
lactic tx threshold, selected by the treating physician, was
10109/L in 61% and 20109/L in 26% of pts. Results: 645 pts
were tx’ed (318 IP vs 327 RP). The primary endpoint, equivalence
of IP to RP in the control of moderate and severe (WHO Grade 2
and higher) bleeding, was demonstrated. Diagnosis (dx) and anti-
neoplastic regimen (SCT vs CTX) were well balanced between IP
and RP. 65% of SCT were autologous (auto) and 35% were
allogeneic (allo); 70% were peripheral blood (PB) and 26% bone
marrow (BM). 86% of PBSCT and 18% of BMT were auto. There
were signiﬁcant differences in dx, plt tx threshold, duration of plt
support, no. of plt and RBC tx, and incidence and duration of
Grade 2 or higher bleeding among auto SCT, allo SCT, and CTX
pts (all p-values  0.01). Leukemia was more common in allo than
auto SCT; lymphoma, plasma cell dyscrasia, and solid tumor were
more common in auto than allo SCT; acute leukemia was the most
common dx for CTX pts (p  0.001). Pts receiving auto SCT had
the lowest tx threshold, shortest duration of plt support, fewest plt
and RBC tx, and the lowest incidence and duration of Grade 2 or
higher bleeding. Allo SCT were on the other extreme, and CTX
pts were intermediate. No difference in incidence or duration of
bleeding was observed between IP and RP for SCT pts. Conclu-
sions: Allo SCT was associated with a longer duration of plt
support, more plt and RBC tx, and a higher incidence and duration
of signiﬁcant bleeding than auto SCT or CTX. INTERCEPT
Platelets were as effective as Reference platelets in control of
Grade 2 and higher bleeding regardless of dx, anti-neoplastic tx, or
stem cell source.
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LONG-TERM, APHERESIS/HEMODIALYSIS CATHETERS DECREASE THE
INCIDENCE OF CATHETER-RELATED BLOOD STREAM INFECTIONS (CR-
BSI) AND VENOUS THROMBOSIS (VT) IN PATIENTS WITH AL AMYLOID-
OSIS (ALA) UNDERGOING HIGH-DOSE MELPHALAN AND AUTOLOGOUS
STEM CELL TRANSPLANT (AUSCT)
Finn, K., Sanchorawala, V., Seldin, D., Kunz, R., Quillen, K. Boston
Medical Center, Boston, MA
Reported catheter-related complications (CRC) during AuSCT
include blood stream infections (BSI), non-patent catheters, cath-
eter site bleeding and VT. ALA patients with nephrotic syndrome
have a greater risk of infection and VT. We performed a retro-
spective review of CRC in 196 ALA patients receiving either a 12
fr non-tunneled catheter (NTC) or a 14 fr tunneled/cuffed cath-
eter (TC). Catheters were intended to be used from stem cell
collection through chemotherapy and re-engraftment, were in-
serted by interventional radiology, and were cared for with the
same catheter care regimen. The majority of the NTC’s (n  103)
were inserted on the left side and the TC (n 93) were inserted on
the right side. The NTC group had 6 CR-BSI and 5 VT, and the
TC group had none. Line patency problems occurred in the NTC
group but not with TC: they were resolved in the NTC group after
the catheter instillation policy was changed from a heparin diluted
with saline solution to approximately 3000U/cc to an undiluted
heparin concentration of 5000U/cc. Bleeding around the catheter
Table. CMV Serostatus and Mortality after HSCT
Donor/Recipient
CMV Serostatus
Hazard Ratio for Mortality
(95% CI)
MSD
(n  749)
MM/URD
(n  1001)
D/R (n  628) 1.0 (ref) 1.0 (ref)
D/R (n  467) 1.07 (0.81-1.42) 1.26 (1.01-1.58)
D/R (n  393) 0.90 (0.65-1.24) 1.29 (1.04-1.60)
D/R (n  262) 0.98 (0.70-1.38) 1.36 (1.06-1.74)
Abbreviations: MSD, matched sibling donor; MM/URD, mis-
matched or unrelated donor.
Table. Study Endpoints for SCT Patients
Endpoint
Auto SCT Allo SCT
IP
(N  154)
RP
(N  171)
P
Value
IP
(N  86)
RP
(N  91)
P
Value
Plt tx threshold
10 109/L (%) 70 68 0.29 48 46 0.82
Grade 2
bleeding
(% pts) 46 51 0.44 73 74 1.00
Grade 3/4
bleeding
(% pts) 0 2 0.25 9 10 1.00
Days of Grade 2
bleeding 1.9 1.4 0.10 5.0 4.9 0.83
Duration plt
support (d) 8.8 7.2 0.05 16.8 16.7 0.88
No. plt tx 5.7 3.7 <0.01 14.0 11.3 0.07
No. RBC tx 3.4 2.7 0.04 6.1 6.6 0.58
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